1. A chip package, comprising:
a base, consisting of:
a patterned circuit layer having a first surface and a second surface opposite to each other; and
a solder mask disposed on the second surface, wherein the solder mask has a plurality of first openings by which a part of the patterned circuit layer is exposed;
a chip disposed on the first surface;
a molding compound covering the pattern circuit layer and fixing the chip onto the patterned circuit layer, wherein the chip is not exposed by the molding compound;
a plurality of outer terminals disposed in the first openings, wherein the outer terminals are electrically connected to the patterned circuit layer, the solder mask and the outer terminals cover the second surface of the patterned circuit layer entirely; and
a plurality of bumps disposed between the chip and the patterned circuit layer, wherein the chip is electrically connected to the patterned circuit layer through the bumps.
2. The chip package as claimed in claim 1, wherein the outer terminals include solder balls.
3. The chip package as claimed in claim 1, further comprising an under fill disposed between the chip and the patterned circuit layer covering the bumps.
4. The chip package as claimed in claim 3, wherein the molding compound and the under fill cover the first surface of the patterned circuit layer entirely.
5. The chip package as claimed in claim 1, wherein the chip is entirely encapsulated by the molding compound.
The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.
1. A method of activating a dopamine receptor, the method comprising contacting the dopamine receptor with an effective amount of the compound having the Formula I:
or a pharmaceutically acceptable salt thereof,
wherein:
the dashed line denotes a saturated or non-saturated bond;
M is \u2014CRb\u2550CRc-;
Q is CRd;
T is CRa;
A is C;
B is N;
D is \u2550C\u2014NR2\u2014;
E is C\u2550O;
K is methylene;
L is N;
Z is \u2014CR6R7\u2014CR8R9\u2014;
G is \u2014CR10R11\u2014CR12R13\u2014;
X is N;
Y has the general formula II:
wherein:
U is CR20;
V is \u2014CR24\u2550CR23\u2014;
W is CR22;
R6-R13 are each independently selected from the group consisting of hydrogen, alkyl, alkenyl, and cycloalkyl;
R21 is hydroxy;
R2, R20 and R22-R24 are each hydrogen; and
Ra-Rd are each independently selected from the group consisting of hydrogen, alkyl, hydroxy, alkoxy, and halide, each being substituted or non-substituted.
2. The method of claim 1, wherein R6-R8 and R10-R11 are selected from the group consisting of hydrogen and methyl.
3. The method of claim 1, wherein R9, R12 and R13 are each hydrogen.
4. The method of claim 1, wherein R6-R13 are each hydrogen.
5. The method of claim 1, wherein Ra is halide.
6. The method of claim 1, wherein Rb is selected from the group consisting of hydrogen and alkoxy.
7. The method of claim 1, wherein Rc is selected from the group consisting of hydrogen, halide and alkyl.
8. The method of claim 1, wherein Rd is selected from the group consisting of hydrogen and alkyl.
9. The method of claim 1, wherein Ra-Rd are each hydrogen.
10. The method of claim 1, wherein said compound has the formula:
11. The method of claim 1, being for treating a condition in which activating a dopamine receptor is beneficial.
12. The method of claim 11, wherein said condition is a sexual disorder.
13. The method of claim 1, wherein said dopamine receptor is a D4 receptor, the compound being characterized as a selective agonist of said D4 receptor.